SG10202108973SA - Improved serum albumin binders - Google Patents

Improved serum albumin binders

Info

Publication number: SG10202108973SA
Authority: SG; Singapore
Prior art keywords: serum albumin; improved serum; albumin binders; binders; improved
Prior art date: 2017-01-17

Application number

SG10202108973SA

Inventor

Stephanie Staelens

Soren Steffensen

Erika Morizzo

An Cerdobbel

Original Assignee

Ablynx Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-01-17

Filing date

2018-01-17

Publication date

2021-09-29

2018-01-17 Application filed by Ablynx Nv filed Critical Ablynx Nv

2021-09-29 Publication of SG10202108973SA publication Critical patent/SG10202108973SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG10202108973SA 2017-01-17 2018-01-17 Improved serum albumin binders SG10202108973SA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762446992P	2017-01-17	2017-01-17

Publications (1)

Publication Number	Publication Date
SG10202108973SA true SG10202108973SA (en)	2021-09-29

Family

ID=61163666

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10202108973SA SG10202108973SA (en)	2017-01-17	2018-01-17	Improved serum albumin binders
SG11201906341XA SG11201906341XA (en)	2017-01-17	2018-01-17	Improved serum albumin binders

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG11201906341XA SG11201906341XA (en)	2017-01-17	2018-01-17	Improved serum albumin binders

Country Status (22)

Country	Link
US (2)	US11897944B2 (en)
EP (3)	EP4442708A3 (en)
JP (3)	JP7300385B2 (en)
KR (2)	KR20230165374A (en)
CN (2)	CN117327175A (en)
AU (2)	AU2018209150B2 (en)
BR (1)	BR112019014600A2 (en)
CA (1)	CA3050574A1 (en)
DK (1)	DK3571224T3 (en)
ES (1)	ES2994387T3 (en)
FI (1)	FI3571224T3 (en)
HR (1)	HRP20241501T1 (en)
HU (1)	HUE068820T2 (en)
IL (3)	IL267897B2 (en)
LT (1)	LT3571224T (en)
MX (4)	MX2019008536A (en)
PL (1)	PL3571224T3 (en)
PT (1)	PT3571224T (en)
RS (1)	RS66173B1 (en)
SG (2)	SG10202108973SA (en)
SI (1)	SI3571224T1 (en)
WO (1)	WO2018134234A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2015261536B2 (en)	2014-05-16	2020-05-07	Ablynx Nv	Improved immunoglobulin variable domains
KR20250099289A (en)	2014-05-16	2025-07-01	아블린쓰 엔.브이.	Improved immunoglobulin variable domains
KR20230061582A (en) *	2016-12-07	2023-05-08	아블린쓰 엔.브이.	Improved serum albumin binding immunoglobulin single variable domains
CN117285623A (en) *	2017-01-17	2023-12-26	埃博灵克斯股份有限公司	Improved serum albumin conjugate
SG10202108973SA (en) *	2017-01-17	2021-09-29	Ablynx Nv	Improved serum albumin binders
MX2022006881A (en)	2019-12-06	2022-07-11	Ablynx Nv	POLYPEPTIDES COMPRISING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULIN TARGETTING TNF ALFA AND OX40L.
WO2021110816A1 (en)	2019-12-06	2021-06-10	Ablynx Nv	POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23
TWI861302B (en)	2019-12-09	2024-11-11	比利時商艾伯霖克斯公司	Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
CA3175873A1 (en)	2020-03-30	2021-10-07	Ablynx Nv	Method for the production and purification of multivalent immunoglobulin single variable domains
TW202229338A (en)	2020-09-25	2022-08-01	比利時商艾伯霖克斯公司	Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
WO2022089435A1 (en) *	2020-10-27	2022-05-05	Beijing Ql Biopharmaceutical Co., Ltd.	Fusion proteins of gdf15 and use thereof
AU2021399955A1 (en)	2020-12-18	2023-08-03	Ablynx Nv	Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
TW202239763A (en)	2020-12-18	2022-10-16	比利時商艾伯霖克斯公司	Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-α
MX2023007299A (en)	2020-12-18	2023-07-04	Ablynx Nv	T cell recruiting polypeptides based on tcr alpha/beta reactivity.
EP4448574A1 (en)	2021-12-17	2024-10-23	Ablynx N.V.	Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
IL316990A (en) *	2022-05-23	2025-01-01	Cereius Inc	Her2-binding agents and uses thereof
AU2023290487A1 (en)	2022-06-14	2025-01-30	Ablynx Nv	Immunoglobulin single variable domains targeting t cell receptor
AU2023313033A1 (en)	2022-07-27	2025-03-13	Ablynx Nv	Polypeptides binding to a specific epitope of the neonatal fc receptor
US20240415974A1 (en)	2022-12-23	2024-12-19	Ablynx N.V.	Protein-based conjugation carriers
CN120529914A (en)	2023-01-09	2025-08-22	奥德赛治疗股份有限公司	Anti-TNFR2 antigen binding protein and its use
KR20250151445A (en)	2023-02-17	2025-10-21	아블린쓰 엔.브이.	Polypeptide that binds to the neonatal FC receptor
CN121263437A (en)	2023-03-14	2026-01-02	奥德赛治疗股份有限公司	Anti-CD 25 antigen binding proteins and uses thereof
AR132699A1 (en)	2023-05-17	2025-07-23	Odyssey Therapeutics Inc	MODIFIED SINGLE DOMAIN ANTIBODIES
WO2024261235A1 (en)	2023-06-22	2024-12-26	Ablynx Nv	Chimeric proteins for modulating cytokine receptor activity
AU2024308381A1 (en)	2023-06-29	2025-11-20	Odyssey Therapeutics, Inc.	Anti-trailr2 antigen-binding proteins and uses thereof
AR133188A1 (en)	2023-07-05	2025-09-03	Ablynx Nv	Improved FcRn antagonists for the treatment of IgG-related diseases and disorders
TW202525843A (en)	2023-09-04	2025-07-01	法商賽諾菲公司	Polypeptides for use in the treatment of glypican-3-expressing tumours
TW202532432A (en)	2023-09-22	2025-08-16	比利時商艾伯霖克斯公司	Bi- and multivalent albumin binders
TW202530265A (en)	2023-10-13	2025-08-01	美商奧迪希治療公司	Anti-cdh17 antigen-binding proteins and uses thereof
AR134267A1 (en)	2023-11-08	2025-12-17	Sanofi Sa	CD25-BASED LYSOSOMAL DEGRADER AND ITS USES
WO2025114529A1 (en)	2023-12-01	2025-06-05	Ablynx Nv	Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
TW202543670A (en)	2023-12-22	2025-11-16	比利時商艾伯霖克斯公司	Protein-based conjugation carriers for intranuclear delivery
WO2025133166A1 (en)	2023-12-22	2025-06-26	Ablynx Nv	Protein-based carriers for site-specific amine conjugation
WO2025217240A1 (en)	2024-04-10	2025-10-16	Odyssey Therapeutics, Inc.	Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025255435A2 (en)	2024-06-07	2025-12-11	Odyssey Therapeutics, Inc.	Antigen-binding proteins against serum albumin and uses thereof
WO2025255558A2 (en)	2024-06-07	2025-12-11	Odyssey Therapeutics, Inc.	Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2026006708A2 (en)	2024-06-27	2026-01-02	Odyssey Therapeutics, Inc.	Anti-cd25 antigen-binding proteins and uses thereof
WO2026006809A1 (en)	2024-06-27	2026-01-02	Odyssey Therapeutics, Inc.	Multispecific molecules binding tnfr2 and cd25 and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU2152299A (en)	1997-10-27	1999-05-24	Unilever Plc	Multivalent antigen-binding proteins
US6742038B2 (en)	2000-04-07	2004-05-25	Danger, Inc.	System and method of linking user identification to a subscriber identification module
JP2005289809A (en)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	Mutant heavy chain antibody
EP1600459A3 (en)	2002-06-28	2005-12-07	Domantis Limited	Ligand
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
JP2006520584A (en)	2002-11-08	2006-09-14	アブリンクスエン．ヴェー．	Stabilized single domain antibody
WO2004062551A2 (en)	2003-01-10	2004-07-29	Ablynx N.V.	RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
CA2588892A1 (en)	2004-12-02	2006-06-08	Dormantis Limited	Anti-il-1r1 single domain antibodies and therapeutic uses
EP3613767A1 (en)	2005-05-18	2020-02-26	Ablynx N.V.	Improved nanobodiestm against tumor cecrosis factor-alpha
KR101414438B1 (en)	2005-05-20	2014-07-10	아블린쓰 엔.브이.	Single domain vhh antibodies against von willebrand factor
CN101466734A (en)	2005-12-01	2009-06-24	杜门蒂斯有限公司	Competitive domain antibody formats that bind interleukin 1 receptor type 1
JP2009519011A (en)	2005-12-01	2009-05-14	ドマンティスリミテッド	Non-competitive domain antibody format that binds to interleukin 1 receptor type 1
FR2894741B1 (en)	2005-12-08	2009-12-04	Centre Nat Etd Spatiales	SATELLITE RECEPTION CHAIN
CA2640066A1 (en)	2006-01-24	2007-08-02	Roland Beckmann	Fusion proteins that contain natural junctions
JP2010500876A (en)	2006-08-18	2010-01-14	アブリンクスエン．ヴェー．	Amino acid sequence directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signaling
US20100113339A1 (en)	2006-09-08	2010-05-06	Ablynx N. V.	Serum albumin binding proteins with long half-lives
CN101796072B (en)	2007-05-24	2014-09-24	埃博灵克斯股份有限公司	Amino acid sequences against RANK-L and polypeptides comprising same for the treatment of bone diseases and disorders
AU2008328781A1 (en)	2007-11-27	2009-06-04	Ablynx N.V.	Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
DE102008023620A1 (en)	2008-05-15	2009-11-19	Mettler-Toledo (Albstadt) Gmbh	Function unit with an invocable function and method for calling it
BRPI0911984A2 (en)	2008-05-16	2016-09-20	Ablynx Nv	amino acid sequences directed against cxcr4 and other gpcrs compounds comprising the same
HUE033438T2 (en)	2008-09-26	2017-11-28	Ucb Biopharma Sprl	Biological products
WO2010130832A2 (en)	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
BR112012001681A2 (en)	2009-07-16	2019-09-24	Graxo Group Ltd	improved serum anti-albumin binding domains
MX2012003939A (en)	2009-09-30	2012-07-30	Glaxo Group Ltd	Drug fusions and conjugates with extended half life.
US9012609B2 (en)	2010-08-13	2015-04-21	Glaxosmithkline Intellectual Property Development Limited	Anti-serum albumin binding variants
US20130230519A1 (en)	2010-08-20	2013-09-05	Elena De Angelis	Anti-serum albumin binding variants
US11644471B2 (en) *	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) *	2010-09-30	2017-04-05	Ablynx N.V.	Biological materials related to c-met
SG10201605048XA (en)	2011-06-23	2016-07-28	Ablynx Nv	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SI2723771T1 (en) *	2011-06-23	2019-12-31	Ablynx Nv	Serum albumin binding proteins
US20150344568A1 (en) *	2011-06-23	2015-12-03	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012174741A1 (en)	2011-06-24	2012-12-27	Google Inc.	Determining cross-language query suggestion based on query translations
TW201321405A (en)	2011-08-17	2013-06-01	Glaxo Group Ltd	Modified protein and peptide
US20130129727A1 (en)	2011-11-17	2013-05-23	Nanjingjinsirui Science & Technology Biology Corporation	Methods and systems for increasing protein stability
WO2014037419A1 (en) *	2012-09-04	2014-03-13	Vib Vzw	Immunoglobulin single variable domains directed against cd74 and uses derived thereof
US20140186365A1 (en)	2013-01-03	2014-07-03	Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center	Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
AU2015261536B2 (en)	2014-05-16	2020-05-07	Ablynx Nv	Improved immunoglobulin variable domains
CN114478753A (en)	2015-01-21	2022-05-13	英伊布里克斯公司	Non-immunogenic single domain antibodies
HUE071467T2 (en)	2015-05-13	2025-08-28	Ablynx Nv	T-cell recruiting polypeptides based on TCR-alpha/-beta reactivity
WO2017070620A2 (en)	2015-10-22	2017-04-27	Modernatx, Inc.	Broad spectrum influenza virus vaccine
EP3380517B1 (en)	2015-11-27	2021-08-04	Ablynx NV	Polypeptides inhibiting cd40l
US11299751B2 (en) *	2016-04-29	2022-04-12	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
KR20230061582A (en) *	2016-12-07	2023-05-08	아블린쓰 엔.브이.	Improved serum albumin binding immunoglobulin single variable domains
CN117285623A (en)	2017-01-17	2023-12-26	埃博灵克斯股份有限公司	Improved serum albumin conjugate
SG10202108973SA (en) *	2017-01-17	2021-09-29	Ablynx Nv	Improved serum albumin binders

2018
- 2018-01-17 SG SG10202108973SA patent/SG10202108973SA/en unknown
- 2018-01-17 CN CN202311114345.5A patent/CN117327175A/en active Pending
- 2018-01-17 SG SG11201906341XA patent/SG11201906341XA/en unknown
- 2018-01-17 HU HUE18703213A patent/HUE068820T2/en unknown
- 2018-01-17 ES ES18703213T patent/ES2994387T3/en active Active
- 2018-01-17 EP EP24191390.4A patent/EP4442708A3/en active Pending
- 2018-01-17 PT PT187032131T patent/PT3571224T/en unknown
- 2018-01-17 LT LTEPPCT/EP2018/051082T patent/LT3571224T/en unknown
- 2018-01-17 WO PCT/EP2018/051082 patent/WO2018134234A1/en not_active Ceased
- 2018-01-17 US US16/477,927 patent/US11897944B2/en active Active
- 2018-01-17 EP EP18703213.1A patent/EP3571224B1/en active Active
- 2018-01-17 KR KR1020237040677A patent/KR20230165374A/en not_active Ceased
- 2018-01-17 JP JP2019538383A patent/JP7300385B2/en active Active
- 2018-01-17 EP EP24191396.1A patent/EP4471058A3/en active Pending
- 2018-01-17 BR BR112019014600-8A patent/BR112019014600A2/en unknown
- 2018-01-17 IL IL267897A patent/IL267897B2/en unknown
- 2018-01-17 IL IL316293A patent/IL316293A/en unknown
- 2018-01-17 FI FIEP18703213.1T patent/FI3571224T3/en active
- 2018-01-17 RS RS20241239A patent/RS66173B1/en unknown
- 2018-01-17 CN CN201880015687.2A patent/CN110461870B/en active Active
- 2018-01-17 PL PL18703213.1T patent/PL3571224T3/en unknown
- 2018-01-17 KR KR1020197024114A patent/KR102653724B1/en active Active
- 2018-01-17 SI SI201831172T patent/SI3571224T1/en unknown
- 2018-01-17 MX MX2019008536A patent/MX2019008536A/en unknown
- 2018-01-17 DK DK18703213.1T patent/DK3571224T3/en active
- 2018-01-17 AU AU2018209150A patent/AU2018209150B2/en active Active
- 2018-01-17 IL IL305912A patent/IL305912B2/en unknown
- 2018-01-17 HR HRP20241501TT patent/HRP20241501T1/en unknown
- 2018-01-17 CA CA3050574A patent/CA3050574A1/en active Pending
2019
- 2019-07-17 MX MX2024008521A patent/MX2024008521A/en unknown
- 2019-07-17 MX MX2024013316A patent/MX2024013316A/en unknown
- 2019-07-17 MX MX2025010630A patent/MX2025010630A/en unknown
2022
- 2022-10-20 JP JP2022168448A patent/JP7585272B2/en active Active
2024
- 2024-01-04 US US18/404,145 patent/US20240294617A1/en active Pending
- 2024-11-06 JP JP2024194438A patent/JP2025024012A/en active Pending
2025
- 2025-04-07 AU AU2025202453A patent/AU2025202453A1/en active Pending

Also Published As

Publication number	Publication date
EP3571224B1 (en)	2024-08-07
RS66173B1 (en)	2024-12-31
MX2025010630A (en)	2025-10-01
SI3571224T1 (en)	2025-01-31
EP4471058A2 (en)	2024-12-04
HRP20241501T1 (en)	2025-01-03
EP4442708A3 (en)	2024-12-25
KR20190104609A (en)	2019-09-10
US20190367598A1 (en)	2019-12-05
ES2994387T3 (en)	2025-01-23
JP7300385B2 (en)	2023-06-29
EP3571224A1 (en)	2019-11-27
MX2024008521A (en)	2024-07-19
SG11201906341XA (en)	2019-08-27
US20240294617A1 (en)	2024-09-05
LT3571224T (en)	2024-11-11
KR20230165374A (en)	2023-12-05
CN110461870A (en)	2019-11-15
IL305912B2 (en)	2025-03-01
MX2019008536A (en)	2019-09-10
JP7585272B2 (en)	2024-11-18
KR102653724B1 (en)	2024-04-02
PL3571224T3 (en)	2025-01-07
CN110461870B (en)	2023-09-29
IL305912B1 (en)	2024-11-01
AU2025202453A1 (en)	2025-04-24
IL267897B2 (en)	2025-02-01
RU2019125949A3 (en)	2021-03-09
JP2025024012A (en)	2025-02-19
FI3571224T3 (en)	2024-11-05
RU2019125949A (en)	2021-02-19
IL305912A (en)	2023-11-01
CA3050574A1 (en)	2018-07-26
BR112019014600A2 (en)	2020-02-18
AU2018209150B2 (en)	2025-01-16
AU2018209150A1 (en)	2019-07-25
DK3571224T3 (en)	2024-11-11
IL267897B1 (en)	2024-10-01
EP4442708A2 (en)	2024-10-09
CN117327175A (en)	2024-01-02
JP2023002700A (en)	2023-01-10
WO2018134234A1 (en)	2018-07-26
US11897944B2 (en)	2024-02-13
HUE068820T2 (en)	2025-01-28
JP2020506898A (en)	2020-03-05
PT3571224T (en)	2024-11-08
IL316293A (en)	2024-12-01
EP4471058A3 (en)	2025-02-26
IL267897A (en)	2019-09-26
MX2024013316A (en)	2024-12-06

Publication	Publication Date	Title
IL267894A (en)	2019-09-26	Improved serum albumin binders
IL267897A (en)	2019-09-26	Improved serum albumin binders
ZA201804317B (en)	2019-09-25	Altered april binding antibodies
SI3583125T1 (en)	2025-06-30	Albumin binding domain fusion proteins
ZA201804601B (en)	2019-04-24	Psma binding antibody and uses thereof
HUE064772T2 (en)	2024-04-28	Binder system
PL3246370T3 (en)	2020-02-28	Heat-sealable binder
ZA201901862B (en)	2020-09-30	Modified factor h binding protein
LT3452515T (en)	2025-12-10	Her-2 binding antibodies
GB201610063D0 (en)	2016-07-27	Binders
ZA201906821B (en)	2021-06-30	Anti-jagged1 antigen binding proteins
GB201615588D0 (en)	2016-10-26	TSLP Binding Proteins
IL267318A (en)	2019-08-29	Binding assay
GB201614627D0 (en)	2016-10-12	Antigen binding proteins
HK1261097A1 (en)	2019-12-27	Improved serum albumin binders
GB201715149D0 (en)	2017-11-01	IL-ß binding antibody
GB201802995D0 (en)	2018-04-11	File serving
IL256197A (en)	2018-02-28	Binding folder
ZA201707980B (en)	2019-05-29	Binding folder
PH32016001013S1 (en)	2016-10-07	Clip binder